dioctanoylphosphatidic acid: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 128167 |
| CHEMBL ID | 202185 |
| CHEBI ID | 79075 |
| SCHEMBL ID | 417239 |
| MeSH ID | M0224533 |
| Synonym |
|---|
| pa(8:0/8:0) |
| LMGP10010021 |
| 1,2-dioctanoyl-sn-glycero-3-phosphatidic acid |
| octanoic acid, 1-[(phosphonooxy)methyl]-1,2-ethanediyl ester, (r)- |
| dioctanoylphosphatidic acid |
| dic8pa |
| 102731-57-7 |
| pa(16:0) |
| CHEMBL202185 , |
| chebi:79075 , |
| octanoic acid (r)-2-octanoyloxy-3-phosphonooxy-propyl ester |
| bdbm50176391 |
| [(2r)-2-octanoyloxy-3-phosphonooxypropyl] octanoate |
| octanoic acid, 1-((phosphonooxy)methyl)-1,2-ethanediyl ester, (r)- |
| 637nlp8r7j , |
| unii-637nlp8r7j |
| SCHEMBL417239 |
| 1,2-dicapryloyl-sn-glycero-3-phosphate |
| (2r)-2,3-bis(octanoyloxy)propyl hydrogen phosphate |
| (2r)-3-(phosphonooxy)propane-1,2-diyl dioctanoate |
| J791.705H , |
| DTXSID70145477 |
| Q27105086 |
| ((2r)-2-octanoyloxy-3-phosphonooxypropyl) octanoate |
| 1,1'-((1r)-1-((phosphonooxy)methyl)-1,2-ethanediyl) dioctanoate |
| octanoic acid, (1r)-1-((phosphonooxy)methyl)-1,2-ethanediyl ester |
| octanoic acid, 1,1'-((1r)-1-((phosphonooxy)methyl)-1,2-ethanediyl)ester |
| Class | Description |
|---|---|
| 1,2-diacyl-sn-glycerol 3-phosphate | An sn-glycerol 3-phosphate compound having unspecified O-acyl groups at the 1- and 2-positions. |
| octanoate ester | Any fatty acid ester in which the carboxylic acid component is octanoic acid (caprylic acid). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
dioctanoylphosphatidic acid is involved in 30 pathway(s), involving a total of 150 unique proteins and 419 unique compounds
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 | Homo sapiens (human) | IC50 (µMol) | 1.6440 | 0.0011 | 1.0958 | 10.0000 | AID260483 |
| Lysophosphatidic acid receptor 1 | Homo sapiens (human) | IC50 (µMol) | 0.6920 | 0.0460 | 1.1827 | 5.5000 | AID260480 |
| Lysophosphatidic acid receptor 1 | Homo sapiens (human) | Ki | 0.4070 | 0.4070 | 1.7107 | 4.3000 | AID260480 |
| Lysophosphatidic acid receptor 3 | Homo sapiens (human) | IC50 (µMol) | 0.0850 | 0.0850 | 0.5648 | 1.6000 | AID260482 |
| Lysophosphatidic acid receptor 3 | Homo sapiens (human) | Ki | 0.0390 | 0.0390 | 0.4396 | 1.6880 | AID260482 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID260480 | Activity at LPA1 receptor transfected RH7777 cells | 2006 | Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3 | Synthesis and pharmacological evaluation of second-generation phosphatidic acid derivatives as lysophosphatidic acid receptor ligands. |
| AID260483 | Inhibition of recombinant ATX from transfected HEK293 cells | 2006 | Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3 | Synthesis and pharmacological evaluation of second-generation phosphatidic acid derivatives as lysophosphatidic acid receptor ligands. |
| AID260482 | Activity at LPA3 receptor transfected RH7777 cells | 2006 | Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3 | Synthesis and pharmacological evaluation of second-generation phosphatidic acid derivatives as lysophosphatidic acid receptor ligands. |
| AID260481 | Activity at LPA2 receptor transfected RH7777 cells | 2006 | Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3 | Synthesis and pharmacological evaluation of second-generation phosphatidic acid derivatives as lysophosphatidic acid receptor ligands. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (53.85) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||